•  
  •  
 

ORCID ID

Egemen Tural: 0009-0007-4772-796X

Ayşe Deniz Ertürk Coşkun: 0000-0003-0658-2366

Gizem Pinar: 0000-0003-3902-2330

Fisun Vural: 0000-0002-1103-7357

Abstract

Background: Overactive bladder syndrome affects millions globally. It can intermittently cause urinary incontinence, which can significantly diminish the quality of life. This study investigated overactive bladder symptoms in premenopausal and postmenopausal individuals by analyzing the influence of demographic, gynecological, and obstetric factors.

Methods: This single-center prospective cross-sectional study was conducted between September 1 and November 1, 2023, among premenopausal and postmenopausal women. In total, 244 patients meeting the inclusion criteria were selected using a simple random method. Participants were asked to complete an information collection form, and the Turkish version of the Overactive Bladder-V8 questionnaire was administered. A significance level of p < 0.05 was considered.

Results: Individuals with an overactive bladder were older (mean age, 46.14 ± 14.56) and had a higher body mass index (mean, 28.47 ± 6.02) than healthy individuals (p = 0.013, p < 0.001, respectively). No significant difference in menopausal status was found (p = 0.091). Urinary incontinence was significantly higher in the overactive bladder group (63.6% vs. 17.4%, p < 0.001). The number of vaginal deliveries and prior gynecologic surgeries differed significantly between the groups (p = 0.030, p = 0.001, respectively).

Conclusions: Age, higher body mass index, vaginal childbirth, and history of gynecological surgeries are associated with overactive bladder frequency, whereas menopausal status did not exert a significant effect.

References

  1. Bo K, Frawley HC, Haylen BT, Abramov Y, Almeida FG, Berghmans B, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for the conservative and nonpharmacological management of female pelvic floor dysfunction. Neurourol Urodyn. 2017;36:221–44.
  2. White N, Iglesia CB. Overactive Bladder. Obstet Gynecol Clin North Am. 2016;43:59–68.
  3. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–14.
  4. Wolff GF, Kuchel GA, Smith PP. Overactive bladder in the vulnerable elderly. Res Rep Urol. 2014;6:131–8.
  5. Sarici H, Ozgur BC, Telli O, Doluoglu OG, Eroglu M, Bozkurt S. The prevalence of overactive bladder syndrome and urinary incontinence in a Turkish women population; associated risk factors and effect on Quality of life. Urologia. 2016;83:93–8.
  6. Rahn DD, Ward RM, Sanses TV, Carberry C, Mamik MM, Meriwether KV, et al. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: Systematic review and practice guidelines. Int Urogynecol J. 2015;26:3–13.
  7. Robinson D, Cardozo L, Milsom I, Pons ME, Kirby M, Koelbl H, et al. Oestrogens and overactive bladder. Neurourol Urodyn. 2014;33:1086–91.
  8. Zhu L, Cheng X, Sun J, Lv S, Mei S, Chen X, et al. Association between menopausal symptoms and overactive bladder: A cross-sectional questionnaire survey in China. PLoS One. 2015;10(10):e0139599.
  9. Zhu J, Hu X, Dong X, Li L. Associations between risk factors and overactive bladder: A meta-analysis. Female Pelvic Med Reconstr Surg. 2019;25:238–46.
  10. Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Qual Life Res. 2002;11:563–74.
  11. Acquadro C, Kopp Z, Coyne KS, Corcos J, Tubaro A, Choo MS, et al. Translating overactive bladder questionnaires in 14 languages. Urology. 2006;67:536–40.
  12. Tarcan T, Mangir N, Ozgur MO, Akbal C. OAB-V8 AAM sorgulama formu validasyon çalışması [OAB-V8 overactive bladder questionnaire validation study]. Üroloji Bülteni. 2012;21:113–6. Turkish.
  13. Gomes CM, Averbeck MA, Koyama M, Soler R. Impact of OAB symptoms on work, quality of life and treatment-seeking behavior in Brazil. Curr Med Res Opin. 2020;36:1403–15.
  14. Sheikh MA, Fawad A, Rabbani KJ, Mazhar SB, Ali S, Yasmin H, et al. Overactive bladder: A multicenter study in Pakistan. J Pak Med Assoc. 2022;72:17–21.
  15. Tikkinen KA, Tammela TL, Rissanen AM, Valpas A, Huhtala H, Auvinen A. Is the prevalence of overactive bladder overestimated? A population-based study in Finland. PLoS One. 2007;2:e195.
  16. Safarinejad MR. Prevalence of the overactive bladder among Iranian women based on the International Continence Society definition: A population-based study. Int Urol Nephrol. 2009;41:35–45.
  17. Al Edwan G, Abdelazim MS, Salhab SE, Jamal YM, Soliman MA. The prevalence of overactive bladder symptoms in women in Algeria, Egypt, Jordan and Lebanon: A cross-sectional population-based survey. Adv Ther. 2021;38:1155–67.
  18. Yang CF, Huang CY, Wang SY, Chang SR. Prevalence of and associated factors for overactive bladder subtypes in middle-aged women: A cross-sectional study. Medicina. 2022;58:383.
  19. Wen JG, Li JS, Wang ZM, Huang CX, Shang XP, Su ZQ, et al. The prevalence and risk factors of OAB in middle-aged and old people in China. Neurourol Urodyn. 2014;33:387–91.
  20. Tunn R, Baessler K, Knüpfer S, Hampel C. Urinary incontinence and pelvic organ prolapse in women. Dtsch Arztebl Int. 2023;120:71–80.
  21. Brown JS, Seeley DG, Fong J, Black DM, Ensrud KE, Grady D. Urinary incontinence in older women: Who is at risk? Study of Osteoporotic Fractures Research Group. Obstet Gynecol. 1996;87:715–21.
  22. Kim SY, Bang W, Choi HG. Analysis of the prevalence of and factors associated with overactive bladder in adult Korean women. PLoS One. 2017;12:e0185592.
  23. Nomiya M, Andersson KE, Yamaguchi O. Chronic bladder ischemia and oxidative stress: New pharmacotherapeutic targets for lower urinary tract symptoms. Int J Urol. 2015;22:40–6.
  24. Kawahara T, Ito H, Yao M, Uemura H. Impact of smoking habit on overactive bladder symptoms and incontinence in women. Int J Urol. 2020;27:1078–86.
  25. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014;21:1063–8.
  26. Nagai K, Homma Y, Ideno Y, Hayashi K. Prevalence and factors associated with overactive bladder and stress urinary incontinence in the Japan Nurses' Health Study. Menopause. 2021;29:129–36.
  27. Christmas MM, Iyer S, Daisy C, Maristany S, Letko J, Hickey M. Menopause hormone therapy and urinary symptoms: A systematic review. Menopause. 2023;30:672–85.
  28. Baruch Y, Torella M, De Bastiani S, Meschia M, Candiani M, Colacurci N, et al. Pre- versus Post-menopausal onset of overactive bladder and the response to vaginal estrogen therapy: A prospective study. Medicina. 2023;59:245.
  29. Ninomiya S, Naito K, Nakanishi K, Okayama H. Prevalence and risk factors of urinary incontinence and overactive bladder in Japanese women. Low Urin Tract Symptoms. 2018;10:308–14.
  30. López-López AI, Sanz-Valero J, Gómez-Pérez L, Pastor-Valero M. Pelvic floor: Vaginal or caesarean delivery? A review of systematic reviews. Int Urogynecol J. 2021;32:1663–73.
  31. Alasmi RA, Saqyan TMB, Alanazi LF, Alharbi MF, Alashgae AF. Urinary incontinence: Comparison study to identify the type, incidence and risk factors between admitted women and the general population in Al-Kharj city, Saudi Arabia. Urol Ann. 2023;15:68–73.
  32. Blomquist JL, Muñoz A, Carroll M, Handa VL. Association of delivery mode with pelvic floor disorders after childbirth. JAMA. 2018;320:2438–47.
  33. Staskin D, Frankel J, Varano S, Kennelly M, Newman DK, Rosenberg MT, et al. Vibegron for the treatment of patients with dry and wet overactive bladder: A subgroup analysis from the EMPOWUR Trial. Int J Clin Pract. 2022;2022:6475014.
  34. Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: Evaluation and management. Curr Urol. 2018;11:117–25.
  35. Przydacz M, Chłosta M, Belch Ł, Czech AK, Wiatr T, Gronostaj K, et al. Treatment patterns for lower urinary tract symptoms and overactive bladder in an Eastern European country: A nationwide population-representative survey. Cent European J Urol. 2021;74:382–87.
  36. Zuluaga L, Caicedo JI, Mogollón MP, Santander J, Bravo-Balado A, Trujillo CG, et al. Anxiety and depression in association with lower urinary tract symptoms: Results from the COBaLT study. World J Urol. 2023;41:1381–8.
  37. Ninomiya S, Kawahara T, Tsutsumi S, Ito H, Makiyama K, Uemura H. Lower urinary tract symptoms are elevated with depression in Japanese women. Low Urin Tract Symptoms. 2023;15:116–21.

Creative Commons License

Creative Commons Attribution-Share Alike 3.0 License
This work is licensed under a Creative Commons Attribution-Share Alike 3.0 License.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.